… that was conducted to determine the efficacy and safety of sequential treatment … study,
our results suggest that intermittent combination treatment of chemotherapy and erlotinib/gefitinib …

… treated with at least one line of chemotherapy. The toxicity profile of erlotinib observed in
this study … Three recent studies have demonstrated that gefitinib, another EGFR TK inhibitor, …

… of gefitinib and erlotinib in ISEL and BR.21 studies. Thus, in many countries and regions,
erlotinib has been approved as standard treatment … Although gefitinib was removed from the US …

… Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third
line, in patients unselected for EGFR mutations; gefitinib was … in this study required toxicity-…

… In this study, treatment of the parental H3255 cell line with gefitinib blocked the phosphorylation
of EGFR. However, unlike the parental cell line, H3255 GR cells maintained a low level …

… ), 49 patients discontinued study treatment due to the following … study of combination
therapy with afatinib plus nimotuzumab in patients with acquired resistance to gefitinib or erlotinib…

… Similarly, in a randomized study that compared erlotinib and gefitinib in the second-line …
, but patients treated with erlotinib experienced more grade 3 or 4 treatment-related adverse …

… the enzyme kinetics of gefitinib and erlotinib metabolism by … were examined by incubating
gefitinib or erlotinib (1.5-50 … presence and absence of gefitinib or erlotinib in human liver and …

… erlotinib-treated patients, respectively. Rash and diarrhea each resulted in study discontinuation
in 1% of erlotinib-treated … similar study, performed in patients receiving gefitinib treatment…

… trial of 150 mg daily (7) assessed the relationship of tumor membrane EGFR staining and
tumor response in patients with NSCLC treated with gefitinib or erlotinib as second-line or third-…